PharmaCyte Biotech, Inc. 4
4 · Q/C TECHNOLOGIES, INC. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
PharmaCyte Biotech, Inc.
10% Owner
Transactions
- Purchase
Warrants
2025-11-14+889,865→ 889,865 totalExp: 2030-11-14→ Common stock, par value $0.001 per share (889,865 underlying) - Purchase
Series H Convertible Preferred Stock
2025-09-04+889,865→ 889,865 total→ Common stock, par value $0.001 per share (889,865 underlying)
Footnotes (1)
- [F1]The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.